AC/SAS:gte 03/11/05 362206.doc PATENT

EXPRESS MAIL LABEL NO. EV510808379US DATE OF DEPOSIT: March 11, 2005 Attorney Reference Number 4239-66903-02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Valenzuela et al.

Application No. Not yet assigned

Filed: Herewith

Confirmation No. Not yet assigned

P. ARIASI POLYPEPTIDES, P.

PERNICIOSUS POLYPEPTIDES AND

METHODS OF USE

Examiner: Not yet assigned Art Unit: Not yet assigned

Attorney Reference No. 4239-66903-02

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV510808379US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent

for Applicant(s)

Date Mailed March 11, 2005

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450** 

## INFORMATION DISCLOSURE STATEMENT **PURSUANT TO 37 C.F.R. § 1.97(b)(2)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several Englishlanguage documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal letter for this IDS is enclosed.

AC/SAS:gte 03/11/05 362206.doc PATENT

EXPRESS MAIL LABEL NO. EV510808379US DATE OF DEPOSIT: March 11, 2005 Attorney Reference Number 4239-66903-02

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Anne Carlson, Ph.D. Registration No. 47,472

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

EXPRESS MAIL LABEL NO. EV510808379US
DATE OF DEPOSIT: March 11, 2005
Attorney Reference Number 4239-66903-02

10/527500

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inve

Attorney Docket Number	4239-66903-02	
Application Number	Not yet assigned	
Filed	Herewith	
First Named Inventor	Valenzuela	
Art Unit	Not yet assigned	
Examiner Name	Not yet assigned	

		Examiner Name Not yet assigned				
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS				
		BARRAL et al., "Human immune response to sand fly salivary gland products is a useful epidemiological marker," Am. J. Trop. Med. Hyg. 62:740-745, 2000				
		BELKAID et al., "Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis," J Exp Med 188, 1941-1953, 1998  BELKAID et al., "Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: An adaptive response induced by the fly?" Proc Natl Acad Sci USA 97, 6704-6709, 2000  CAMPBELL, Monoclonal Antibody Technology. New York: Elsevier Science Publishing				
		Co., Inc., pages 1-32, 1984  SAMBROOK et al., eds., Molecular Cloning: A Laboratory Manual, 2 <sup>nd</sup> edition. Cold Spring Harbor Laboratory Press, Vol. 3, pages 16.2 – 16.81, 1989				
		TITUS et al., "Salivary gland lysates of the sand fly Lutzomyia longipalpis enhance Leishmania infectivity," Science 239(4845):1306-1308, 1988				
-		VALENZUELA et al., "Toward a defined anti-Leishmania vaccine targeting vector antigens: Characterization of a protective salivary protein," J. Exp. Med. 194:331-342, 2001				
		Database A_Genseq_29June04 Accession No. ABB71995, 26 March 2002, 1 page				
		Database A_Genseq_29June04 Accession No. ABG718028, 18 Feb 2002, 1 page				
		Database SPTrEMBL Accession No. Q95WD8, 19 Dec 2001, 6 pages				
		Database SPTrEMBL Accession No. Q23404, 6 June 1998, 5 pages				
		Database A_Genseq_29June04 Accession No. AAG03191, 6 Oct 2000, 1 page				
		Database A_Genseq_29June04 Accession No. ABG24332, 18 Feb 2002, 1 page				
		Database SPTrEMBL Accession No. Q9HNC7 16 March 2001, 4 pages				

	D. A. MC
EXAMINER	DATE
SIGNATURE:	CONSIDERED:
	L

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO. EV510808379US DATE OF DEPOSIT: March 11, 2005 Attorney Reference Number 4239-66903-02

## DT15 Rec'd PCT/PTO \_1 1 MAR 2005

	Attorney Docket Number	4239-66903-02			
	Application Number	Not yet assigned			
INFORMATION DISCLOSURE STATEMENT	Filed	Herewith			
BY APPLICANT	First Named Inventor	Valenzuela			
	Art Unit	Not yet assigned			
	Examiner Name	Not yet assigned			
Database A_Genseq_29June04 Acc	cession No. AAU48010, 27 F	eb 2002, 1 page			
Database SPTrEMBL Accession N	o. Q95WE2, 1 Dec 2001, 1 p	age			
Database PIR_78 Accession No. G	Database PIR_78 Accession No. G81431, 31 March 2000, 2 pages				
Database SPTrEMBL Accession N	Database SPTrEMBL Accession No. Q9XZ44, 12 Nov 1999, 4 pages				
Database A_Genseq_29June04 Acc	Database A_Genseq_29June04 Accession No. AAB94843 26 June 2001, 1 page				
Database A_Genseq_29June04 Acc	Database A_Genseq_29June04 Accession No. ABB61398, 26 March 2002, 1 page				
Database A_Genseq_29June04 Acc	Database A_Genseq_29June04 Accession No. AAB42952, 08 Feb 2001, 1 page				
Database SPTrEMBL Accession N	Database SPTrEMBL Accession No. Q9RVD4, 1 May 2000, 1 page				
Database SPTrEMBL Accession N	Database SPTrEMBL Accession No. Q95WE2, 1 Dec 2001, 2 pages				
Database PIR_78 Accession No. B	Database PIR_78 Accession No. B64020, 10 Sep 1999, 1 page				
Database A_Genseq_29June04 Acc	Database A_Genseq_29June04 Accession No. ABB57882, 26 March 2002, 1 page				
Database PIR_78 Accession No. T.	Database PIR_78 Accession No. T50116, 9 June 2000, 1 page				
Database PIR_78 Accession No. F	Database PIR_78 Accession No. F90270, 24 May 2001, 1 page				
Database A_Genseq_29June04 Acc	Database A_Genseq_29June04 Accession No. ABB58845, 26 March 2002, 1 page				
Database A_Genseq_29June04 Acc	Database A_Genseq_29June04 Accession No. AAB83185, 9 July 2001, 1 page				
Database Swissprot_42 Accession	Database Swissprot_42 Accession No. Q57124, 10 Nov 1997, 1 page				
	<del></del>				

	ATE ONSIDERED:
--	----------------

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.